The DrugAge database of aging-related drugs

Abstract

SummaryAging is a major worldwide medical challenge. Not surprisingly, identifying drugs and compounds that extend lifespan in model organisms is a growing research area. Here, we present DrugAge (http://genomics.senescence.info/drugs/), a curated database of lifespan‐extending drugs and compounds. At the time of writing, DrugAge contains 1316 entries featuring 418 different compounds from studies across 27 model organisms, including worms, flies, yeast and mice. Data were manually curated from 324 publications. Using drug–gene interaction data, we also performed a functional enrichment analysis of targets of lifespan‐extending drugs. Enriched terms include various functional categories related to glutathione and antioxidant activity, ion transport and metabolic processes. In addition, we found a modest but significant overlap between targets of lifespan‐extending drugs and known aging‐related genes, suggesting that some but not most aging‐related pathways have been targeted pharmacologically in longevity studies. DrugAge is freely available online for the scientific community and will be an important resource for biogerontologists.

Gene expression‐based drug repurposing to target aging

“…The DrugAge database reports drug‐induced lifespan extensions up to 1.5‐fold for Caenorhabditis elegans, 1.1‐fold for Drosophila melanogaster and 31% for Mus musculus (Barardo et al, 2017). Some of these chemicals may mimic the effects of DR (Fontana et al, 2010).…”

“…Another study generated a combined score reflecting both the aging relevance of drugs based on the GenAge database and GO annotations as well as the likely efficacy of the drugs in model organisms, using structural analyses and other criteria such as solubility (Ziehm et al, 2017). A machine learning approach has been used to identify prolongevity drugs based on the chemical descriptors of the drugs in DrugAge database and GO annotations of their targets (Barardo et al, 2017). Using DrugAge as a training set, the results reflect the known pathways in aging, and thus identified anticancer and antiinflammatory drugs, compounds related to mitochondrial process and gonadotropin‐releasing hormone antagonists.…”

Can Pension Funds Partially Manage Longevity Risk by Investing in a Longevity Megafund?

“…In 2008, Ayyadevara et al (2008) were able to extend the lifespan of laboratory nematodes by circa ten times with one single gene change and Bartke et al (2008) were able to extend the lifespan of laboratory mice by 70% with a combination of gene change and diet. Since then, a vast range of successful methods in animals were reproduced at the level of cells and tissues in humans and human trials are now being discussed (see Barardo et al 2017). The translatability to humans is supported by several discoveries.…”

Studying the geroprotective effects of inhibitors suppressing aging -associated signaling cascades in model organisms

“…The elevation of researchers' interest to anti-aging drugs took place in 1960s, which was connected to endeavours of «Free Radical Theory of Aging» (by Denham Harman [21]) evaluation, as well as with discovery of phenomenon of longevity hormesis [44]. At the present day, according to Geroprotectors.org (http://geroprotectors.org/) [36] and DrugAge (http:// genomics.senescence.info/drugs/) [4] databases, found more than 200 geroprotectors. However the lifespan-extending effects of pharmacological interventions surpass the threshold of 20-40 % very seldom, mutations of aging genes and over expression of longevity genes usually have more significant impact.…”

“…In the outer circle you see the pharmacological groups of drugs and compound which form these groups. The scheme is based on materials of DrugAge (http://genomics.senescence.info/ drugs/) [4] and Geroprotectors.org (http://geroprotectors.org/) [36] databases references reviews ОБЗОРы…”